Fig. 4
From: Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
Infliximab survival (percentage responders) over the 5-year study. “Cum” survival = cumulative survival
Fig. 4 | BMC Musculoskeletal Disorders
